EA201790305A1 - КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE - Google Patents

КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE

Info

Publication number
EA201790305A1
EA201790305A1 EA201790305A EA201790305A EA201790305A1 EA 201790305 A1 EA201790305 A1 EA 201790305A1 EA 201790305 A EA201790305 A EA 201790305A EA 201790305 A EA201790305 A EA 201790305A EA 201790305 A1 EA201790305 A1 EA 201790305A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
disease
alzheimer
monoclonal antibodies
combined therapy
Prior art date
Application number
EA201790305A
Other languages
English (en)
Other versions
EA031764B1 (ru
Inventor
Патрик Корнелиус Мэй
Дастин Джеймс Мерготт
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201790305A1 publication Critical patent/EA201790305A1/ru
Publication of EA031764B1 publication Critical patent/EA031764B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

Настоящее изобретение обеспечивает способ лечения когнитивного или нейродегенеративного заболевания, включающий введение пациенту, нуждающемуся в указанном лечении, эффективного количества соединения формулыили его фармацевтически приемлемой соли; в комбинации с эффективным количеством моноклонального антитела к N3pGlu Абета.
EA201790305A 2014-09-16 2015-09-08 КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3PGLU Аβ И ИНГИБИТОРА BACE EA031764B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462050967P 2014-09-16 2014-09-16
PCT/US2015/048807 WO2016043997A1 (en) 2014-09-16 2015-09-08 Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor

Publications (2)

Publication Number Publication Date
EA201790305A1 true EA201790305A1 (ru) 2017-07-31
EA031764B1 EA031764B1 (ru) 2019-02-28

Family

ID=54207720

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790305A EA031764B1 (ru) 2014-09-16 2015-09-08 КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3PGLU Аβ И ИНГИБИТОРА BACE

Country Status (27)

Country Link
US (1) US9999624B2 (ru)
EP (1) EP3193882A1 (ru)
JP (1) JP6339741B2 (ru)
KR (1) KR101871128B1 (ru)
CN (1) CN106687136A (ru)
AP (1) AP2017009794A0 (ru)
AR (1) AR101740A1 (ru)
AU (1) AU2015318257B2 (ru)
BR (1) BR112017003571A2 (ru)
CA (1) CA2956835A1 (ru)
CL (1) CL2017000558A1 (ru)
CO (1) CO2017001875A2 (ru)
CR (1) CR20170080A (ru)
DO (1) DOP2017000071A (ru)
EA (1) EA031764B1 (ru)
EC (1) ECSP17015977A (ru)
IL (1) IL250387A0 (ru)
MX (1) MX2017003414A (ru)
NZ (1) NZ728636A (ru)
PE (1) PE20170464A1 (ru)
PH (1) PH12017500493A1 (ru)
SG (1) SG11201701330PA (ru)
SV (1) SV2017005389A (ru)
TN (1) TN2017000072A1 (ru)
TW (1) TWI599358B (ru)
WO (1) WO2016043997A1 (ru)
ZA (1) ZA201700826B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180119670A (ko) * 2016-03-15 2018-11-02 아스트라제네카 아베 아밀로이드 베타의 축적과 관련된 질환의 치료를 위한 bace 억제제와 항체 또는 항원 결합 단편의 조합
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
WO2018034977A1 (en) 2016-08-18 2018-02-22 Eli Lilly And Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
MA46621A (fr) 2016-10-28 2021-06-02 H Lundbeck As Traitements combinés comprenant l'administration d'imidazopyrazinones
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
US11634416B2 (en) 2017-12-14 2023-04-25 H. Lundbeck A/S Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
CN111511742B (zh) 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
US10350226B1 (en) 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections
US20230236199A1 (en) * 2020-04-23 2023-07-27 Eli Lilly And Company Subcutaneous absorption and bioavailability of antibodies
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662816B2 (en) 2003-08-08 2010-02-16 Schering Corporation Cyclic amine BACE-1 inhibitors having a benzamide substituent
RU2476431C2 (ru) 2008-01-18 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Конденсированное производное аминодигидротиазина
CN103068848B (zh) 2010-08-12 2015-11-25 伊莱利利公司 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物

Also Published As

Publication number Publication date
ZA201700826B (en) 2018-12-19
CL2017000558A1 (es) 2017-11-10
SV2017005389A (es) 2018-01-17
JP6339741B2 (ja) 2018-06-06
AU2015318257B2 (en) 2018-06-14
TN2017000072A1 (en) 2018-07-04
JP2017529348A (ja) 2017-10-05
KR101871128B1 (ko) 2018-06-25
KR20170036103A (ko) 2017-03-31
CN106687136A (zh) 2017-05-17
US20170224702A1 (en) 2017-08-10
PE20170464A1 (es) 2017-04-26
EP3193882A1 (en) 2017-07-26
CA2956835A1 (en) 2016-03-24
CO2017001875A2 (es) 2017-05-19
CR20170080A (es) 2017-03-30
AP2017009794A0 (en) 2017-03-31
NZ728636A (en) 2018-05-25
US9999624B2 (en) 2018-06-19
WO2016043997A1 (en) 2016-03-24
BR112017003571A2 (pt) 2017-12-19
SG11201701330PA (en) 2017-04-27
EA031764B1 (ru) 2019-02-28
DOP2017000071A (es) 2017-06-15
PH12017500493A1 (en) 2017-08-07
IL250387A0 (en) 2017-03-30
AR101740A1 (es) 2017-01-11
TW201618786A (zh) 2016-06-01
ECSP17015977A (es) 2018-03-31
TWI599358B (zh) 2017-09-21
AU2015318257A1 (en) 2017-02-16
MX2017003414A (es) 2017-06-19

Similar Documents

Publication Publication Date Title
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
EA201891286A1 (ru) АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201692472A1 (ru) Соединения для лечения рака мозга
EA201891925A1 (ru) Антитела к cd40 с усиленной агонистической активностью
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201990400A1 (ru) Соединения и композиции и их применение
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA202090414A1 (ru) Соединения и их применение
EA201990988A1 (ru) Антитела против chikv и пути их применения
EA201792610A1 (ru) Способ лечения неврологического заболевания
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU